BioSpace News Archive

Genentech, a member of the Roche Group, announced new data from the Phase III IMbrave050 study that show Tecentriq® plus Avastin® demonstrated a statistically significant improvement in recurrence-free survival in people with hepatocellular carcinoma at high risk of disease recurrence following liver resection or ablation with curative intent.

Positive results from the AEGEAN Phase III trial showed that treatment with AstraZeneca’s IMFINZI® in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery led to a statistically significant and clinically meaningful improvement in event-free survival versus neoadjuvant chemotherapy alone followed by surgery for patients with resectable early-stage non-small cell lung cancer.

Adela, Inc. presented data demonstrating the ability of its genome-wide methylome enrichment platform to detect a broad set of diverse cancers in early stages, when treatment can be most effective.

Accent Therapeutics presented data supporting DHX9 inhibition as a novel cancer treatment approach at the American Association for Cancer Research Annual Meeting 2023 in Orlando, Florida.

As a global innovative biopharmaceutical company, Henlius is committed to offering high-quality, affordable and innovative biopharmaceuticals to patients worldwide with 5 products launched in China.

DiaCarta, Ltd., a precision molecular diagnostics company, announced that it will present five data posters at the American Association of Cancer Research Annual Meeting 2023, which convenes in Orlando, Florida from April 14-19, 2023.

Vivace Therapeutics, Inc. announced that the first clinical data for a cancer treatment targeting the Hippo pathway was presented at the American Association for Cancer Research Annual Meeting 2023.

Otsuka Pharmaceutical Development & Commercialization, Inc., and Lundbeck Pharmaceuticals LLC announce the Joint Meeting of the Psychopharmacologic Drugs Advisory Committee and the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. FDA met to discuss the supplemental New Drug Application of REXULTI® for the treatment of agitation associated with Alzheimer’s dementia.

Innovent Biologics, Inc. announced that the final analysis results of ORIENT-15, the Phase 3 study evaluating sintilimab in combination with chemotherapy for the first-line treatment of esophageal squamous cell carcinoma were released in a poster presentation at the American Association for Cancer Research Annual Meeting 2023.

Abbisko announced the results of five latest preclinical studies at the 2023 American Association for Cancer Research annual meeting.